Patient characteristics (N=35; per-protocol population)
| Age, years | |
| Mean±SD | 36.8±10.96 |
| Median (min., max.) | 37.0 (22, 63) |
| Sex, n (%) female | 21 (60.0) |
| Race, n (%) Caucasian | 35 (100) |
| Education | |
| Primary education (basic, semiskilled), n (%) | 9 (25.7) |
| Secondary education (eg, apprenticeship, technical college), n (%) | 20 (57.1) |
| Tertiary education (university degree), n (%) | 6 (17.1) |
| Occupation | |
| Employed, n (%) | 23 (65.7) |
| Unemployed, n (%) | 7 (20.0) |
| Housewife, n (%) | 3 (8.6) |
| Undergoing further education, n (%) | 2 (5.7) |
| Disease duration | |
| <1 year, n (%) | 8 (22.9) |
| 1–6 years, n (%) | 12 (34.3) |
| 6–12 years, n (%) | 10 (28.6) |
| >13 years, n (%) | 5 (14.3) |
| Patients with at least one prior DMT, n (%) | 28 (80.0) |
| Previous interferon-β 1A SC treatment, n (%) | 16 (45.7) |
| Previous interferon-β 1A IM treatment, n (%) | 7 (20.0) |
| Previous interferon-β 1B treatment, n (%) | 2 (5.7) |
| Previous fingolimod treatment, n (%) | 11 (31.4) |
| Previous glatiramer acetate treatment, n (%) | 7 (20.0) |
| Previous dimethyl fumarate treatment, n (%) | 5 (14.3) |
| Previous teriflunomide treatment, n (%) | 4 (11.4) |
| Previous natalizumab treatment, n (%) | 1 (2.9) |
| Other treatment, n (%) | 1 (2.9) |
| Relapses in history cv | |
| Yes | 34 (97.1) |
| No | 1 (2.9) |
| No of MS relapses in 12 months prior to natalizumab treatment | |
| Mean±SD | 1.2±0.94 |
| Median (min., max.) | 0 (0, 4) |
| Baseline no of relapses requiring corticosteroid treatment per year in: | |
| EDSS improved group, mean±SD | 0.9±0.9 |
| EDSS stable group, mean±SD | 0.6±0.6 |
| Baseline EDSS score | |
| Mean±SD | 3.04±1.19 |
| Median (min., max.) | 3.00 (1.00, 5.50) |
| Baseline MusiQoL score | |
| Mean±SD | 66.7±13.8 |
| Median (min., max.) | 65.6 (40.2, 94.4) |
DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; IM, intramuscular; MS, multiple sclerosis; MusiQoL, Multiple Sclerosis International Quality of Life questionnaire; MusiQoL, Multiple Sclerosis International Quality of Life; SC, subcutaneous.